Notice

Biomanufacturing Fund (BMF): Phase 2 (closed to applications)

This fund is to support commercial-scale vaccines and biotherapeutics manufacturing projects that will improve the UK’s health resilience for future pandemics.

Documents

Grant offer letter draft template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alt.formats@dsit.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

As part of the £4.5 billion funding for strategic manufacturing sectors at the Autumn Statement 2023, we have made available £520 million funding for life sciences manufacturing over five years (2025-2030).

This funding will build resilience for future health emergencies and capitalise on the UK’s world-leading research and development capabilities. An announcement will be made via our Office for Life Sciences newsletter. If you would like to be added to the copy list, please email Futurecapitalfund@officeforlifesciences.gov.uk.

The Biomanufacturing Fund (BMF) Phase 2 is closed to new applications.

The Biomanufacturing Fund (BMF) will provide up to £38 million in capital grants to incentivise investment in the manufacture of vaccines and biotherapeutics, to improve the UK’s health resilience for future pandemics.

Background and objectives of the programme

The BMF follows on from the £60 million Life Sciences Innovative Manufacturing Fund and the £20 million Medicines and Diagnostics Manufacturing Transformation Fund.

Specific themes

We particularly welcome applications for the manufacture of:

  • drug substance (for example active pharmaceutical ingredient (API)
  • finished drug product (for example fill/finish)
  • component materials (such as starting materials, delivery systems, adjuvants)

for the following product categories:

  • vaccines: all vaccine modalities
  • biotherapeutics: including monoclonal antibodies and cell-and-gene therapies

This list is not exhaustive.

Fund objectives

We will prioritise applicants based on their alignment to the fund’s objectives:

1. Increasing health resilience in the UK for future pandemics through increased domestic capacity, or by providing flexible capabilities that have the ability to be re-deployed;

2. Creating economic opportunity through investments that will make a substantial contribution to Gross Value Added and provide high-wage, high-skilled jobs.

Contact

Contact the BMF Project Team if you have any queries about the fund: bmf@officeforlifesciences.gov.uk.

Published 25 May 2023
Last updated 26 February 2024 + show all updates
  1. Biomanufacturing Fund (BMF): Phase 2 closed to applications.

  2. Deadline to submit a Expression of Interest (EOI) form changed to 12pm (midday) on Friday 17 November 2023.

  3. Biomanufacturing Fund (BMF): phase 2 open to expressions of interest.

  4. First published.